Your browser doesn't support javascript.
loading
Modeling the Prognostic Impact of Circulating Tumor Cells Enumeration in Metastatic Breast Cancer for Clinical Trial Design Simulation.
Gerratana, Lorenzo; Pierga, Jean-Yves; Reuben, James M; Davis, Andrew A; Wehbe, Firas H; Dirix, Luc; Fehm, Tanja; Nolé, Franco; Gisbert-Criado, Rafael; Mavroudis, Dimitrios; Grisanti, Salvatore; Garcia-Saenz, Jose A; Stebbing, Justin; Caldas, Carlos; Gazzaniga, Paola; Manso, Luis; Zamarchi, Rita; Bonotto, Marta; Fernandez de Lascoiti, Angela; De Mattos-Arruda, Leticia; Ignatiadis, Michail; Sandri, Maria-Teresa; Generali, Daniele; De Angelis, Carmine; Dawson, Sarah-Jane; Janni, Wolfgang; Carañana, Vicente; Riethdorf, Sabine; Solomayer, Erich-Franz; Puglisi, Fabio; Giuliano, Mario; Pantel, Klaus; Bidard, François-Clément; Cristofanilli, Massimo.
Afiliação
  • Gerratana L; Department of Medical Oncology, Centro di Riferimento Oncologico (CRO), IRCCS, Aviano (PN), Italy.
  • Pierga JY; Department of Medical Oncology, Institut Curie, Paris & Saint-Cloud, Paris University, Paris, France.
  • Reuben JM; Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Davis AA; Division of Hematology and Oncology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
  • Wehbe FH; Department of Medicine, Division of Oncology, Washington University School of Medicine in St. Louis, MO, USA.
  • Dirix L; Division of Hematology and Oncology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
  • Fehm T; Translational Cancer Research Unit, GZA Hospitals Sint-Augustinus, Antwerp, Belgium.
  • Nolé F; Department of Gynecology and Obstetrics, Heinrich Heine University Düsseldorf, Düsseldorf, Germany.
  • Gisbert-Criado R; Medical Oncology Division of Urogenital and Head & Neck Tumours IEO, European Institute of Oncology IRCCS, Milan, Italy.
  • Mavroudis D; Clinical Laboratory, Hospital Arnau de Vilanova, Valencia, Spain.
  • Grisanti S; Laboratory of Translational Oncology, School of Medicine, University of Crete, Heraklion, Greece.
  • Garcia-Saenz JA; Department of Medical Oncology, University Hospital of Heraklion, Greece.
  • Stebbing J; epartment of Transfusion Medicine, Laboratory for Stem Cells Manipulation and Cryopreservation, AO Spedali Civili di Brescia, Brescia, Italy.
  • Caldas C; Instituto de Investigación Sanitaria Hospital Clinico San Carlos (IdISSC), CIBERONC, Madrid, Spain.
  • Gazzaniga P; Division of Cancer, Department of Surgery and Cancer, Imperial College London, London, UK.
  • Manso L; Cancer Research UK Cambridge Institute and Department of Oncology Li Ka Shing Centre, University of Cambridge, Cambridge, UK.
  • Zamarchi R; Department of Molecular Medicine, Sapienza University of Rome, Rome, Italy.
  • Bonotto M; Hospital 12 de Octubre, Madrid, Spain.
  • Fernandez de Lascoiti A; Veneto Institute of Oncology IOV - IRCCS, Padua, Italy.
  • De Mattos-Arruda L; Department of Oncology, ASUFC University Hospital, Udine, Italy.
  • Ignatiadis M; Hospital de Navarra, Pamplona, Spain.
  • Sandri MT; Val d'Hebron Institute of Oncology, Val d'Hebron University Hospital, and Universitat Autònoma de Barcelona, Barcelona, Spain.
  • Generali D; Department of Medical Oncology and Breast Cancer Translational Research Laboratory, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium.
  • De Angelis C; Division of Laboratory Medicine, Humanitas Reseach Hospital, Rozzano, Milan, Italy.
  • Dawson SJ; Women Cancer Center, Azienda Socio-Sanitaria Territoriale di Cremona, Cremona, Italy.
  • Janni W; University of Trieste, Trieste, Italy.
  • Carañana V; Department of Clinical Medicine and Surgery, University Federico II, Naples, Italy.
  • Riethdorf S; Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, TX, USA.
  • Solomayer EF; Centre for Cancer Research and Sir Peter MacCallum Department of Oncology, The University of Melbourne, VIC, Australia.
  • Puglisi F; Frauenklinik, University of Ulm, Ulm, Germany.
  • Giuliano M; Clinical Oncology, Hospital Arnau de Vilanova, Valencia, Spain.
  • Pantel K; Department of Tumor Biology, Center of Experimental Medicine, University Cancer Center Hamburg, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
  • Bidard FC; Saarland University, Homburg, Germany.
  • Cristofanilli M; Department of Medical Oncology, Centro di Riferimento Oncologico (CRO), IRCCS, Aviano (PN), Italy.
Oncologist ; 27(7): e561-e570, 2022 07 05.
Article em En | MEDLINE | ID: mdl-35278078
ABSTRACT
Despite the strong prognostic stratification of circulating tumor cells (CTCs) enumeration in metastatic breast cancer (MBC), current clinical trials usually do not include a baseline CTCs in their design. This study aimed to generate a classifier for CTCs prognostic simulation in existing datasets for hypothesis generation in patients with MBC. A K-nearest neighbor machine learning algorithm was trained on a pooled dataset comprising 2436 individual MBC patients from the European Pooled Analysis Consortium and the MD Anderson Cancer Center to identify patients likely to have CTCs ≥ 5/7 mL blood (StageIVaggressive vs StageIVindolent). The model had a 65.1% accuracy and its prognostic impact resulted in a hazard ratio (HR) of 1.89 (Simulatedaggressive vs SimulatedindolentP < .001), similar to patients with actual CTCs enumeration (HR 2.76; P < .001). The classifier's performance was then tested on an independent retrospective database comprising 446 consecutive hormone receptor (HR)-positive HER2-negative MBC patients. The model further stratified clinical subgroups usually considered prognostically homogeneous such as patients with bone-only or liver metastases. Bone-only disease classified as Simulatedaggressive had a significantly worse overall survival (OS; P < .0001), while patients with liver metastases classified as Simulatedindolent had a significantly better prognosis (P < .0001). Consistent results were observed for patients who had undergone CTCs enumeration in the pooled population. The differential prognostic impact of endocrine- (ET) and chemotherapy (CT) was explored across the simulated subgroups. No significant differences were observed between ET and CT in the overall population, both in terms of progression-free survival (PFS) and OS. In contrast, a statistically significant difference, favoring CT over ET was observed among Simulatedaggressive patients (HR 0.62; P = .030 and HR 0.60; P = .037, respectively, for PFS and OS).
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Ensaios Clínicos como Assunto / Neoplasias Hepáticas / Células Neoplásicas Circulantes Tipo de estudo: Observational_studies / Prognostic_studies Limite: Female / Humans Idioma: En Revista: Oncologist Assunto da revista: NEOPLASIAS Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Itália

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Ensaios Clínicos como Assunto / Neoplasias Hepáticas / Células Neoplásicas Circulantes Tipo de estudo: Observational_studies / Prognostic_studies Limite: Female / Humans Idioma: En Revista: Oncologist Assunto da revista: NEOPLASIAS Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Itália